https://oncdata.com/article/a44f4ac1-3296-4898-9131-54948cdd3317Oncology Data Advisoren2026-11-12T22:49:17.075ZPrognostic Nomogram for Supratentorial H3 K27-Altered Diffuse Midline Glioma: IPD Meta-Analysis https://oncdata.com/article/6479ec08-1310-4728-b7ed-12f4e182b92dOncology Data Advisoren2026-11-12T12:49:44.695ZNo OS or PFS Advantage With Targeted Agents or Immunotherapy in Glioblastoma https://oncdata.com/article/007f2c14-275a-4f45-ad86-7af85d9b12bfOncology Data Advisoren2026-11-12T12:49:44.549ZPalbociclib Regimen in HR+/HER2+ Breast Cancer With Brain Metastases: Phase 2 Trial Results https://oncdata.com/article/ee5ebc20-0a45-4f31-a36c-f9b56025a143Oncology Data Advisoren2026-11-11T22:49:56.405ZPhase III DIAMOND-2 Trial: Dirozalkib vs Crizotinib in Advanced ALK-Positive NSCLC https://oncdata.com/article/8168c585-e20f-468d-8eb8-864dc2839431Oncology Data Advisoren2026-11-11T12:49:45.553ZMTAP Loss Prevalence and PRMT5 Inhibitor Activity in Oncogene-Driven and Oncogene-Negative NSCLC https://oncdata.com/article/9e3f3541-7d7f-4fb5-ad51-571e36159cb4Oncology Data Advisoren2026-11-11T12:49:45.450ZGuidelines for Measurable Residual Disease Assessment in Acute Lymphoblastic Leukemia https://oncdata.com/article/3c98794f-0635-421f-ad72-6b55a6b81149Oncology Data Advisoren2026-11-11T02:49:21.123ZPatients With Refractory iMCD May Respond to a Second IL-6 Inhibitor https://oncdata.com/article/282436ab-b63e-4ecf-be3e-8aef6bab55efOncology Data Advisoren2026-11-11T02:49:21.004ZCSCO and ASCO Joint Guideline for Recurrent and Metastatic Nasopharyngeal Carcinoma